Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.68 |
| ▸ | USP2 | O75604 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.45 |
| ▸ | TPMT | P51580 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.44 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.44 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.44 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.44 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.44 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.44 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9752762 | 0.88 | CYP3A4 (0.78) | CYP3A4USP2MAPK1SMN1; SMN2LMNA | |
| SCHEMBL684391 | 0.85 | CYP3A4 (0.64) | CYP3A4USP2MAPK1SMN1; SMN2LMNA | |
| SCHEMBL11321057 | 0.85 | CYP3A4 (0.54) | CYP3A4USP2MAPK1SMN1; SMN2LMNA | |
| SCHEMBL4608589 | 0.84 | CYP3A4 (0.56) | CYP3A4USP2MAPK1SMN1; SMN2LMNA | |
| SCHEMBL10498389 | 0.84 | CYP3A4 (0.55) | CYP3A4USP2MAPK1SMN1; SMN2LMNA | |
| SCHEMBL9752827 | 0.84 | CYP3A4 (0.60) | CYP3A4USP2MAPK1SMN1; SMN2LMNA | |
| SCHEMBL13601793 | 0.81 | CYP3A4 (1.00) | CYP3A4USP2MAPK1SMN1; SMN2LMNA | |
| SCHEMBL27497325 | 0.79 | MAPT (0.64) | CYP3A4MAPTTPMTTDP1GRIN2D | |
| SCHEMBL9752687 | 0.78 | CYP3A4 (0.65) | CYP3A4USP2MAPK1SMN1; SMN2LMNA | |
| SCHEMBL29612139 | 0.77 | CYP3A4 (0.58) | CYP3A4USP2MAPK1SMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2984072-B1 | SYNTHETIC ANALOGUES OF XANTHOHUMOL | UNIV PISA (IT) | 2024-05-29 | — | — | EP | disclosed |
| WO-2023127291-A1 | METHOD FOR PRODUCING DEMETHYLNOBILETIN | 花王株式会社 | 2023-07-06 | — | — | WO | disclosed |
| WO-2023127291-A1 | METHOD FOR PRODUCING DEMETHYLNOBILETIN | 花王株式会社 | 2023-07-06 | — | — | WO | disclosed |
| WO-2023287249-A1 | METHOD FOR PRODUCING GOSSYPETIN | 주식회사 노브메타파마 | 2023-01-19 | — | — | WO | disclosed |
| US-9617213-B2 | Synthetic analogues of xanthohumol | UNIVERSITA' DI PISA (IT) | 2017-04-11 | — | — | US | disclosed |
| US-20160075652-A1 | SYNTHETIC ANALOGUES OF XANTHOHUMOL | AZIENDA OSPEDALIERA DI REGGIO EMILIA ARCISPEDALE S. MARIA NUOVA IRCCS (IT) | 2016-03-17 | — | — | US | disclosed |
| EP-2311472-B1 | COGNITIVE DISORDER-AMELIORATING AGENT | JAPAN ROYAL JELLY CO LTD (JP) | 2014-03-05 | — | — | EP | disclosed |
| US-20130129832-A1 | COGNITIVE IMPAIRMENT AMELIORANT | TOHOKU UNIVERSITY (JP) | 2013-05-23 | — | — | US | disclosed |
| US-20130129832-A1 | COGNITIVE IMPAIRMENT AMELIORANT | TOHOKU UNIVERSITY (JP) | 2013-05-23 | — | — | US | disclosed |
| US-20110287106-A1 | COGNITIVE IMPAIRMENT AMELIORANT | JAPAN ROYAL JELLEY CO., LTD. (JP) | 2011-11-24 | — | — | US | disclosed |
| US-20110287106-A1 | COGNITIVE IMPAIRMENT AMELIORANT | JAPAN ROYAL JELLEY CO., LTD. (JP) | 2011-11-24 | — | — | US | disclosed |
| EP-2311472-A1 | COGNITIVE DISORDER-AMELIORATING AGENT | Japan Royal Jelly Co., Ltd. (JP) | 2011-04-20 | — | — | EP | disclosed |
| EP-2311472-A1 | COGNITIVE DISORDER-AMELIORATING AGENT | Japan Royal Jelly Co., Ltd. (JP) | 2011-04-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160075652-A1 | SYNTHETIC ANALOGUES OF XANTHOHUMOL | XDH, XPA, NR1H3 | CYP3A4 1728/4885USP2 3282/4885MAPK1 4437/4885 |
| US-20130129832-A1 | COGNITIVE IMPAIRMENT AMELIORANT | CHAT, ACHE, PSEN1 | CYP3A4 4098/4885USP2 2016/4885MAPK1 2783/4885 |
| US-20110287106-A1 | COGNITIVE IMPAIRMENT AMELIORANT | CHAT, ACHE, PSEN1 | CYP3A4 4098/4885USP2 2016/4885MAPK1 2783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.